Spain and Italy have limited the use of the AstraZeneca COVID-19 vaccine for people over the age of 60, which could slow down the European Union’s slow immunization program, which is lagging behind countries such as the United States, the United Kingdom and Israel.
Vaccine and very rare cases of blood clotting problems in adults. The EMA recommended that there be no age restrictions, as it stressed that the benefits of the shot outweigh the risks.
The Italian Ministry of Health recommended that the vaccine only be used for people over the age of 60, but it said that those under the age of 60 who have already received the first dose of AstraZeneca can also take a second dose.
Last month, the French and German health officials Restriction of AstraZeneca injection to those over 55 and over 60, respectively, after concerns about unusual blood clots in some recipients.
Earlier on Wednesday, the United Kingdom’s Joint Commission on Vaccination and Immunization (JCVI) changed its guidelines on vaccination, recommending people Less than 30 Get alternate shots, such as the one jointly developed by BioNTech
First, because of the rare “fading” side effect of blood clots in the brain.
Shares in AstraZeneca were up 2.04% in morning London trade on Thursday. Stocks are down less than 1% in the year so far, according to data from FactSet.
Spain and Italy’s decision to restrict syringe use could make it difficult for the European Union to achieve its goal of vaccination 70% Of its adult population by the end of summer.
The 27-member bloc has already failed to reach its first stage of receiving at least 80% of people over 80 and 80% of healthcare workers against COVID-19 by the end of March, according to the latest data from European Center for Disease Prevention and Control.
The frequency of vaccinations may pick up later this month when the Johnson & Johnson Pharmaceutical Company begins
Delivery of the single-shot COVID-19 vaccine to the European Union begins. The block signed a confirmed order for 200 million J&J doses and an option for another 200 million doses.
On Wednesday, AstraZeneca acknowledged results from EMA and UK Medicines and Healthcare Products Regulatory Agency, Noting that both reviews “confirmed again that the vaccine provides a high level of protection against all the severity of COVID-19 and that these benefits still far outweigh the risks.”
The British-Swedish pharmaceutical company said it is working with global regulators to better understand individual cases, epidemiology and potential mechanisms that could explain these extremely rare events.
Separately on wednesday, World Health Organization The Vaccine Safety Advisory Committee said that although the blood clot connection was “reasonable” it was “not confirmed”, and cases were “very rare” among the 200 million people vaccinated with AstraZeneca globally.
More to track …
Bulletin Observer Business News
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?